Kane Biotech ( (TSE:KNE) ) has issued an update.
Kane Biotech has entered into a three-year distribution agreement with Best Buy Medical Canada for its revyve™ Antimicrobial Wound Gel, following Health Canada approval in November 2024. This strategic partnership aims to expand access to the wound care solution across Canada, targeting hospitals, clinics, and long-term care facilities. The collaboration is expected to enhance patient care and outcomes while tapping into the Canadian wound care market’s financial potential.
More about Kane Biotech
Kane Biotech Inc. is a biotechnology company focused on the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company holds a portfolio of biotechnologies, intellectual property, and products developed through its own biofilm research and collaborations with research institutions. Kane Biotech is publicly traded on the TSX Venture Exchange and the OTCQB Venture Market.
YTD Price Performance: -18.18%
Average Trading Volume: 71,904
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$12.38M
See more insights into KNE stock on TipRanks’ Stock Analysis page.